Antimicrobial Agents and Chemotherapy

Journal

Publication Venue For

  • Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection 2019
  • Pharmacokinetics of dapivirine transfer into blood plasma, breast milk, and cervicovaginal fluid of lactating women using the dapivirine vaginal ring 2019
  • A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.  63. 2019
  • In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms.  62. 2018
  • Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis.  62. 2018
  • In vitro study of the susceptibility of clinical isolates of trichomonas vaginalis to metronidazole and secnidazole.  62. 2018
  • In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China.  61. 2017
  • In vitro activities of gepotidacin (GSK2140944) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  61. 2017
  • Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.  61. 2017
  • In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  60:7502-7504. 2016
  • Emtricitabine-Triphosphate in dried blood spots as a marker of recent dosing.  60:6692-6697. 2016
  • 8-Hydroxyquinolines are boosting agents of copper-related toxicity in Mycobacterium tuberculosis.  60:5765-5776. 2016
  • Antistaphylococcal β-lactams versus vancomycin for treatment of infective endocarditis due to methicillin-susceptible coagulase-negative staphylococci: A prospective cohort study from the international collaboration on endocarditis.  60:6341-6349. 2016
  • In vitro exposure to PC-1005 and cervicovaginal lavage fluid from women vaginally administered PC-1005 inhibits HIV-1 and HSV-2 infection in human cervical mucosa.  60:5459-5466. 2016
  • Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner.  59:4835-4844. 2015
  • In Vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas.  59:3627-3629. 2015
  • Candida infective endocarditis: An observational cohort study with a focus on therapy.  59:2365-2373. 2015
  • The mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules.  59:2328-2336. 2015
  • Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.  59:570-578. 2015
  • Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.  58:7182-7187. 2014
  • Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments.  58:1451-1457. 2014
  • Microbicidal power of alpha radiation in sterilizing germinating Bacillus anthracis spores.  58:1813-1815. 2014
  • Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureus.  58:3727-3736. 2014
  • Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women.  58:4014-4019. 2014
  • Reply to "acute sinusitis and pharyngitis as inappropriate indications for antibiotic use".  58:3573. 2014
  • Association of higher plasma vitamin d binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional Vitamin D deficiency?.  57:5619-5628. 2013
  • Azithromycin to prevent bronchopulmonary dysplasia in Ureaplasma-infected preterm infants: Pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.  57:2127-2133. 2013
  • Real-time treatment guidelines: Considerations during the Exserohilum rostratum outbreak in the United States.  57:1573-1576. 2013
  • Copper-boosting compounds: A novel concept for antimycobacterial drug discovery.  57:1089-1091. 2013
  • Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.  56:5938-5945. 2012
  • Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis.  56:5839-5844. 2012
  • Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.  56:5374-5380. 2012
  • Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.  56:3133-3137. 2012
  • Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States.  56:2780-2783. 2012
  • Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents.  55:5054-5062. 2011
  • A high-throughput screening assay for inhibitors of bacterial motility identifies a novel inhibitor of the Na + -driven flagellar motor and virulence gene expression in Vibrio cholerae.  55:4134-4143. 2011
  • Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.  55:4290-4294. 2011
  • In Vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance network.  55:3944-3946. 2011
  • A new small molecule specifically inhibits the cariogenic bacterium Streptococcus mutans in multispecies biofilms.  55:2679-2687. 2011
  • Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae.  55:2714-2728. 2011
  • Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.  55:1106-1113. 2011
  • Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.  54:4137-4142. 2010
  • Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas.  54:2437-2447. 2010
  • Evaluation of vancomycin and daptomycin potency trends (MIC Creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006 (Antimicrobial Agents and Chemotherapy (2009) 53, 10, (4127-4132)).  54:1383. 2010
  • Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.  54:707-717. 2010
  • Inhibition of herpesvirus replication by 5-substituted 4′- thiopyrimidine nucleosides.  53:5251-5258. 2009
  • Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006.  53:4127-4132. 2009
  • Authors' reply.  53:2705-2706. 2009
  • Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.  53:2139-2141. 2009
  • Activities of certain 5-substituted 4′-thiopyrimidine nucleosides against orthopoxvirus infections.  53:572-579. 2009
  • Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.  53:4015-4018. 2009
  • Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.  52:3776-3778. 2008
  • Association of fluconazole pharmacodynamics with mortality in patients with candidemia.  52:3022-3028. 2008
  • Role of porins for uptake of antibiotics by Mycobacterium smegmatis.  52:3127-3134. 2008
  • Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.  52:2503-2511. 2008
  • Dectin-1 Fc targeting of Aspergillus fumigatus beta-glucans augments innate defense against invasive pulmonary aspergillosis.  52:1171-1172. 2008
  • Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.  52:631-637. 2008
  • Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.  51:4297-4302. 2007
  • Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.  51:3104-3110. 2007
  • Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.  51:2208-2210. 2007
  • Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.  51:1795-1803. 2007
  • EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.  51:1055-1063. 2007
  • Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole.  50:4209-4210. 2006
  • Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.  50:3479-3484. 2006
  • Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.  50:2751-2755. 2006
  • Enteroviral meningitis: Natural history and outcome of pleconaril therapy.  50:2409-2414. 2006
  • Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.  50:1982-1988. 2006
  • New Mycobactenum avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors.  49:4801-4803. 2005
  • Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.  49:3762-3769. 2005
  • Lipophilic antifolate trimetrexate is a potent inhibitor of trypanosoma cruzi: Prospect for chemotherapy of chagas' disease.  49:3234-3238. 2005
  • Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.  49:2541-2542. 2005
  • Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.  49:2294-2301. 2005
  • Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.  49:952-958. 2005
  • Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis.  48:4163-4170. 2004
  • Insufficient Evidence that Extended-Spectrum Cephalosporins Effectively Prevent Metastatic Infections Related to Klebsiella pneumoniae-Caused Liver Abscess.  48:3640-3641. 2004
  • SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.  48:3556-3558. 2004
  • Bis-Anthracycline Antibiotics Inhibit Human Immunodeficiency Virus Type 1 Transcription.  48:1652-1663. 2004
  • Orally active fusion inhibitor of respiratory syncytial virus..  48:413-422. 2004
  • Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?.  48:430-436. 2004
  • Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.  47:3973-3975. 2003
  • Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.  47:3149-3154. 2003
  • Uptake of nitrobenzylthioinosine and purine β-L-nucleosides by intracellular Toxoplasma gondii.  47:3247-3251. 2003
  • Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.  47:2685-2687. 2003
  • Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp..  47:636-642. 2003
  • Prevalence of plasmid-mediated quinolone resistance.  47:559-562. 2003
  • In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.  47:39-42. 2003
  • In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  47:161-165. 2003
  • Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.  46:1896-1905. 2002
  • Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study.  45:3487-3496. 2001
  • Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.  45:3065-3069. 2001
  • Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics.  45:2771-2774. 2001
  • Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.  45:2126-2128. 2001
  • Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.  45:236-242. 2001
  • Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.  44:2672-2678. 2000
  • Intracellular metabolism of β-L-2',3'-dideoxyadenosine: Relevance to its limited antiviral activity.  44:853-858. 2000
  • Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.  44:496-503. 2000
  • Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.  44:2784-2793. 2000
  • In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.  43:2571-2573. 1999
  • Metabolism and selective toxicity of 6-nitrobenzylthioinosine in Toxoplasma gondii.  43:2437-2443. 1999
  • In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.  42:3315-3316. 1998
  • Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae [3] (multiple letters).  42:1869-1870. 1998
  • Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial.  42:1139-1145. 1998
  • Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group..  42:1139-1145. 1998
  • Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.  41:881-885. 1997
  • Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.  40:2775-2780. 1996
  • Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.  40:2721-2726. 1996
  • Structure-activity relationships of quinolone agents against Mycobacteria: Effect of structural modifications at the 8 position.  40:2363-2368. 1996
  • Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections.  40:2202-2205. 1996
  • Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group..  40:2202-2205. 1996
  • Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.  39:1704-1710. 1995
  • Mutacin II, a bactericidal lantibiotic from Streptococcus mutans.  39:2656-2660. 1995
  • Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991.  39:917-920. 1995
  • Decreased susceptibility to penicillin G and tet M plasmids in genital and anorectal isolates of Neisseria meningitidis.  38:1661-1663. 1994
  • In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.  35:1181-1185. 1991
  • INVITRO SUSCEPTIBILITY OF MUTANS STREPTOCOCCI TO ANTIMICROBIAL SUBSTANCES AS DETERMINED BY A MEMBRANE TRANSFER ASSAY.  34:153-155. 1990
  • In vitro susceptibility of mutans streptococci to antimicrobial substances as determined by a membrane transfer assay..  34:153-155. 1990
  • Prevention for tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis.  33:824-827. 1989
  • Azole antifungal agents: Emphasis on new triazoles.  32:1-8. 1988
  • In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.  32:1500-1502. 1988
  • In vitro susceptibilities of suspected periodontopathic anaerobes as determined by membrane transfer assay.  31:1989-1993. 1987
  • Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers.  31:1317-1322. 1987
  • In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.  30:25-30. 1986
  • Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84..  27:309-313. 1985
  • High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.  28:265-273. 1985
  • Clinical evaluation of moxalactam.  20:88-97. 1981
  • Penetration of spectinomycin into cerebrospinal fluid during experimental meningitis.  17:286-287. 1980
  • Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans.  18:709-715. 1980
  • Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. bronchopulmonary infections.  15:807-812. 1979
  • In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.  16:864-868. 1979
  • Increased antibiotic resistance of Neisseria gonorrhoeae in Korea.  9:716-718. 1976
  • International Standard Serial Number (issn)

  • 0066-4804
  • Electronic International Standard Serial Number (eissn)

  • 1098-6596